Patents by Inventor Alan Diamond

Alan Diamond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220057416
    Abstract: A home testing kit used to collect a blood sample of the user and a method of blood analysis used to calculate correct mixtures of THC and CBD for each patient's desired therapeutic benefit.
    Type: Application
    Filed: December 23, 2019
    Publication date: February 24, 2022
    Inventor: Alan DIAMOND
  • Publication number: 20100255491
    Abstract: A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.
    Type: Application
    Filed: June 14, 2010
    Publication date: October 7, 2010
    Inventors: Vadim N. Gladyshev, Dolph L. Hatfield, Kuan Teh Jeang, Alan Diamond, John C. Wootton
  • Patent number: 7776607
    Abstract: A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: August 17, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of Illinois
    Inventors: Vadim N. Gladyshev, Dolph L. Hatfield, Kuan-Teh Jeang, Alan Diamond, John C. Wootton
  • Publication number: 20090087852
    Abstract: A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.
    Type: Application
    Filed: September 22, 2008
    Publication date: April 2, 2009
    Inventors: VADIM N. GLADYSHEV, DOLPH L. HATFIELD, KUAN-TEH JEANG, ALAN DIAMOND, JOHN C. WOOTTON
  • Patent number: 7442543
    Abstract: A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: October 28, 2008
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Board of Trustees of the University of Illinois
    Inventors: Vadim N. Gladyshev, Dolph L. Hatfield, Kuan-Teh Jeang, Alan Diamond, John C. Wootton
  • Patent number: 6849417
    Abstract: A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: February 1, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Vadim N. Gladyshev, Dolph L. Hatfield, Kuan-Teh Jeang, Alan Diamond, John C. Wootton